Female/male, n (%) | 16 (36%)/29 (64%) |
Age, years | 68 ± 10 (47–83) |
Body weight, kg | 71 ± 17 (39–114) |
Body height, m | 1.71 ± 0.1 (1.49–1.87) |
BMI, kg/m2 | 24.3 ± 4.8 (15.0–36.8) |
Blood glucose level at time of injection, mg/dl | 101 ± 17 (67–157) |
Injected tracer activity, MBq | 175 ± 73 (85–318) |
PET/CT scan post injection time, min | 62 ± 9 (51–97) |
Lung tumor localization, n (%) | |
Peripheral | 29 (64%) |
Peri-hilar | 16 (36%) |
Lung cancer stage, n (%)a | |
I | 4 (10%) |
II | 5 (12%) |
III | 12 (29%) |
IV | 20 (49%) |